Moderna Just Gave Investors 499 Million Reasons to Worry

Moderna (NASDAQ: MRNA) announced its second-quarter results before the market opened on Wednesday. And it easily beat Wall Street's expectations.

The vaccine maker reported Q2 revenue of $4.7 billion, up nearly 7% year over year and higher than the consensus estimate of $4.07 billion. Moderna posted earnings per share of $5.24, well above the average analysts' estimate of $4.55.

With these positive numbers, the vaccine stock unsurprisingly jumped around 16% in early trading on Wednesday. But Moderna also just gave investors 499 million reasons to worry.

Source Fool.com